Skip to main content

Sangamo Therapeutics Announces Participation at Upcoming Investor Conferences

ⓘ This article is third-party content and does not represent the views of this site. We make no guarantees regarding its accuracy or completeness.

Sangamo Therapeutics, Inc. (Nasdaq: SGMO), a genomic medicine company, announced today that management will be participating in the following investor conferences:

  • Bank of America Securities Conference

    Date: Wednesday, May 11th at 3:00 p.m. Eastern Time
  • RBC Global Healthcare Conference

    Date: Wednesday, May 18th at 3:05 p.m. Eastern Time
  • H.C. Wainwright Global Investment Conference

    Date: Tuesday, May 24th at 7:00 a.m. Eastern Time

Access links for presentations, panels and fireside chats will be available on the Sangamo Therapeutics website in the Investors and Media section under Events and Presentations. The presentations will also be available on the Sangamo Therapeutics website after the event.

About Sangamo Therapeutics

Sangamo Therapeutics is a clinical-stage biopharmaceutical company with a robust genomic medicines pipeline. Using ground-breaking science, including our proprietary zinc finger genome engineering technology and manufacturing expertise, Sangamo aims to create new genomic medicines for patients suffering from diseases for which existing treatment options are inadequate or currently don’t exist. For more information about Sangamo, visit www.sangamo.com.

Contacts

Report this content

If you believe this article contains misleading, harmful, or spam content, please let us know.

Report this article

Recent Quotes

View More
Symbol Price Change (%)
AMZN  265.06
+0.00 (0.00%)
AAPL  271.35
+0.00 (0.00%)
AMD  354.49
+0.00 (0.00%)
BAC  53.46
+0.00 (0.00%)
GOOG  381.94
+0.00 (0.00%)
META  611.91
+0.00 (0.00%)
MSFT  407.78
+0.00 (0.00%)
NVDA  199.57
+0.00 (0.00%)
ORCL  161.39
+0.00 (0.00%)
TSLA  381.63
+0.00 (0.00%)
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.